医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

DEXLEVO’s 26 Billion Won Pre-IPO Spurs Global Marketing of ‘GOURI’

2022年06月20日 AM10:00
このエントリーをはてなブックマークに追加


 

SEOUL, South Korea

As the spread of COVID-19 has slowed down worldwide, the demand for skincare is expected to increase, and expectations for the rapid growth of the skincare market are also growing. Other countries such as the United States, United Kingdom, and Germany have already lifted the measures to wear masks outdoors, and there is a trend to abolish the measures to wear masks in public transportation. This can be recognized as good news for companies in the beauty industry with a high proportion of overseas exports.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220518005556/en/

GOURI, a liquid PCL injection developed by DEXLEVO (Photo: Business Wire)

GOURI, a liquid PCL injection developed by DEXLEVO (Photo: Business Wire)

DEXLEVO, a company specializing in cosmetic medical devices, has completed pre-IPO funding of 26 billion won for existing investors, Magna Investment, Smilegate Investment, Hyundai Technology Investment, and Shinhan Capital. It is preparing for listing in 2023, and DEXLEVO has set a post value of 276 billion won after investment.

DEXLEVO was established in 2013 by Jaewon Yoo, a former researcher at Samyang Corporation, and succeeded in liquefying Polycaprolactone (PCL), a biodegradable polymer, for the first time in the world. Based on this technology, DEXLEVO developed a liquid PCL injection ‘GOURI’ and participated in the world’s largest beauty fair AMWC (Aesthetic and Anti-aging Medicine world Congress) in September of last year and March of this year as a main sponsor to announce GOURI’s technological prowess and excellence. It will also participate in the International Master Course on Aging Science (IMCAS) held in Paris this June to spur marketing activities to increase its global market share.

Unlike existing fillers, as GOURI is in a liquid form without particulates, it spreads throughout the face when injected and induces collagen formation.

DEXLEVO is expanding its beauty market share with not only GOURI, a cosmetic medical device, but also KABELLINE, a contour product, and Touch BR, a whitening product. Currently, DEXLEVO is focusing on distribution in Southeast Asian regions such as Indonesia, Vietnam, and Thailand. KABELLINE is reaching the Americas.

KABELLINE is a contouring product that breaks down fat using deoxycholic acid. Unlike existing contouring products, there is no pain or side effects, and it is a product that fundamentally prevents the yo-yo effect from resynthesizing free fatty acids (FFA) remaining in the body into fat.

Touch BR is a whitening product with peptide and vitamin C as its main ingredients. It prevents skin aging and melanin production, and improves skin moisture. You can find more information on the DEXLEVO website (www.dexlevoaesthetic.com).

View source version on businesswire.com: https://www.businesswire.com/news/home/20220518005556/en/

CONTACT

DEXLEVO

Business Planning Development

Diana Kim

diana.kim@dexlevo.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 《新英格兰医学杂志》发表Fazirsiran治疗α-1抗胰蛋白酶缺乏症患者的二期研究结果
  • Twist Bioscience and Ildong Pharmaceutical Enter into a Collaboration to Enhance Antibody Discovery for Applications in Immuno-oncology
  • 沃博联结束战略评估,决定保留表现优异的博姿业务
  • BeiGene Announces Late-Breaking Data at ESMO GI Showing Overall Survival Benefit for Tislelizumab Plus Chemotherapy in First-Line Advanced or Metastatic Esophageal Squamous Cell Carcinoma
  • Work for Humankind:联想技术为偏远岛屿开启无限可能